A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab

NCT00379431 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Early and Severe Systemic Sclerosis

Interventions

DRUG: Administration of rituximab and methylprednisolone

Sponsor

University Hospital, Ghent